Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of “Buy” from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $26.43.

A number of research analysts have weighed in on CPRX shares. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Citigroup started coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Finally, Oppenheimer restated an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares of the company’s stock, valued at $2,045,678.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CPRX. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Catalyst Pharmaceuticals by 4.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 1,290 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Catalyst Pharmaceuticals by 5.3% in the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 1,456 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 15.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,719 shares during the period. Finally, Cerity Partners LLC raised its holdings in shares of Catalyst Pharmaceuticals by 11.5% in the 4th quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 1,780 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Down 2.9 %

CPRX opened at $14.68 on Friday. The company has a market cap of $1.73 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.89. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $17.76. The company has a 50-day moving average price of $15.50 and a 200 day moving average price of $14.61.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The business had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. As a group, sell-side analysts expect that Catalyst Pharmaceuticals will post 1.81 earnings per share for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.